# Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis

> **NCT05569538** · PHASE2 · UNKNOWN · sponsor: **The University of Hong Kong** · enrollment: 40 (estimated)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** Bomedemstat

## Key facts

- **NCT ID:** NCT05569538
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05569538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05569538, "Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT05569538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*